Chugai Pharmaceutical Co Revenue 2024

The Chugai Pharmaceutical Co Revenue history

YEAR	REVENUE (undefined JPY)	GROSS MARGIN (%)
2026e	1.19	58,42
2025e	1.15	60,65
2024e	1.1	63,30
2023	1.11	62,81
2022	1.26	62,19
2021	1	66,22
2020	0.79	65,25
2019	0.69	61,42
2018	0.58	54,66
2017	0.53	52,42
2016	0.49	49,58
2015	0.5	51,84
2014	0.46	52,71
2013	0.42	55,87
2012	0.39	57,13
2011	0.37	57,83
2010	0.38	57,20
2009	0.43	55,04
2008	0.33	61,15
2007	0.34	60,18
2006	0.33	59,19
2005	0.33	63,49
2004	0.29	62,15

Chugai Pharmaceutical Co Aktienanalyse

What does Chugai Pharmaceutical Co do?

Chugai Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1925. It is headquartered in Tokyo and employs over 7,500 employees worldwide. Chugai is one of the largest pharmaceutical companies in Japan and has become a global company with a strong research and development department in recent decades. The business model of Chugai is based on the development and production of drugs for various medical conditions, with a focus on cancer therapy. However, Chugai also has drugs for other medical conditions in its portfolio, such as rheumatism, asthma, and diabetes. The company specializes in research and development of biotechnological therapeutics and has focused on the study of biological agents. Chugai's goal is to improve people's lives and enhance patient care. Chugai is divided into several business units, each focusing on different areas of therapy. One of these areas is oncology. Chugai has a strong range of oncology products, for which it is a market leader in Japan. These include Avastin, an anti-angiogenesis drug for the treatment of colorectal, breast, lung, and kidney cancer, as well as Herceptin for the treatment of breast and gastric cancer, and Tarceva for treating bronchial carcinomas. Another important business area of Chugai is rheumatology. Here, Chugai offers various products such as Actemra, a monoclonal antibody against the interleukin-6 receptor used in rheumatoid arthritis, as well as Rituxan, an antibody against the CD20 antigen used in the treatment of lymphomas. In addition to drug development and manufacturing, Chugai also conducts research and development in the field of diagnostics. This is an important complement to the company's therapeutic portfolio. Chugai develops diagnostics to improve disease diagnosis. Another important area of Chugai is the outsourcing of research and development services. Chugai collaborates with many international pharmaceutical companies, offering its expertise and infrastructure in the development of new drugs. Chugai Pharmaceuticals is a significant player in global healthcare and aims to establish itself as a leading company in biological and cellular preparation research. The company invests significant resources in the exploration of new technologies to ensure sustainable therapy options. Chugai Pharmaceuticals has built a strong presence in the global market in recent years and will continue to play an important role in the future. Chugai Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Chugai Pharmaceutical Co's Sales Figures

The sales figures of Chugai Pharmaceutical Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Chugai Pharmaceutical Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Chugai Pharmaceutical Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Chugai Pharmaceutical Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Chugai Pharmaceutical Co Stock

How much revenue did Chugai Pharmaceutical Co generate this year?

Chugai Pharmaceutical Co has achieved a revenue of 1.1 T JPY this year.

How much was the turnover of the company Chugai Pharmaceutical Co compared to the previous year?

The revenue of Chugai Pharmaceutical Co has increased by -0.77% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Chugai Pharmaceutical Co?

The revenue of Chugai Pharmaceutical Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Chugai Pharmaceutical Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Chugai Pharmaceutical Co so important for investors?

The revenue of Chugai Pharmaceutical Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Chugai Pharmaceutical Co pay?

Over the past 12 months, Chugai Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 1.57 %. For the coming 12 months, Chugai Pharmaceutical Co is expected to pay a dividend of 93.2 JPY.

What is the dividend yield of Chugai Pharmaceutical Co?

The current dividend yield of Chugai Pharmaceutical Co is 1.57 %.

When does Chugai Pharmaceutical Co pay dividends?

Chugai Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Chugai Pharmaceutical Co?

Chugai Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Chugai Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 93.2 JPY are expected. This corresponds to a dividend yield of 1.83 %.

In which sector is Chugai Pharmaceutical Co located?

Chugai Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Chugai Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Chugai Pharmaceutical Co from 3/1/2025 amounting to 41 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Chugai Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Chugai Pharmaceutical Co in the year 2023?

In the year 2023, Chugai Pharmaceutical Co distributed 78 JPY as dividends.

In which currency does Chugai Pharmaceutical Co pay out the dividend?

The dividends of Chugai Pharmaceutical Co are distributed in JPY.